Fibrosis as a Therapeutic Target Post-Myocardial Infarction

E-ISSN： 1873-4286|11|4|477-487

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.11, Iss.4, 2005-02, pp. : 477-487

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population

By Benge Cassandra D Muldowney James A S

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 11, 2012-11 ,pp. : 1469-1482

Informa Healthcare

Access to resources Recommend Favorite

Calcium Antagonists in the Post-Myocardial Infarction Setting

By Bertolet B.D.

Drugs & Aging, Vol. 15, Iss. 6, 1999-12 ,pp. : 461-470

Adis International

Access to resources Recommend Favorite

Underutilization of -Adrenoceptor Antagonists Post-Myocardial Infarction

By Gutierrez Michael E. Labovitz Arthur J.

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 1, 2005-01 ,pp. : 23-29

Adis International

Access to resources Recommend Favorite

Regenerative Approaches to Post-Myocardial Infarction Heart Failure

Current Pharmaceutical Design, Vol. 20, Iss. 12, 2014-04 ,pp. : 1930-1940

Bentham Science Publishers

Access to resources Recommend Favorite

Tissue Engineering for Post-Myocardial Infarction Ventricular Remodeling

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 3, 2011-01 ,pp. : 263-270

Bentham Science Publishers

Access to resources Recommend Favorite